Literature DB >> 2564680

Cachectin alters anterior pituitary hormone release by a direct action in vitro.

L Milenkovic1, V Rettori, G D Snyder, B Beutler, S M McCann.   

Abstract

Cachectin (tumor necrosis factor) is a powerful macrophage hormone released during infection, which circulates in blood to produce diverse effects in the organism. We examined the effect of cachectin on release of anterior pituitary hormones from either hemipituitaries or dispersed pituitary cells incubated in vitro. The action of cachectin on dispersed cells was demonstrable only after 2 hr of incubation. With this incubation time, the protein produced a dose-related stimulation of release of adrenocorticotropin (ACTH), growth hormone (GH), and thyrotropin (TSH), but not of prolactin (Prl), from both hemipituitaries and dispersed cells. The doses required for stimulation were low in the case of hemipituitaries, usually of the order of 10(-12) M, whereas they were higher by one or two orders of magnitude with the dispersed pituitary cells. This may be related either to loss of receptors for the protein during the dispersion procedure or to the fact that in the hemipituitary system cell interactions are facilitated because the cells are close to each other. In the dispersed cell system cachectin evoked a dose-related decrease in cyclic AMP content. Incubation with somatostatin lowered the cyclic AMP content of the cells and depressed GH output without altering output of TSH or Prl. When somatostatin and cachectin were incubated together with the cells, the suppression of cyclic AMP production was abolished; TSH and Prl release were stimulated, but the action of cachectin to stimulate GH release was blocked. The stimulation of Prl release by cachectin in the presence of somatostatin may be related to the elevation of cyclic AMP, a known stimulator of Prl release. The cyclooxygenase inhibitor indomethacin nearly completely blocked the stimulatory effect of cachectin on release of GH and TSH from dispersed pituitary cells but had only a slight and nonsignificant attenuating effect on its ACTH-releasing action. These results suggest that at least part of the stimulatory action of the peptide on pituitary hormone release is brought about by prostaglandins. The failure of indomethacin to block the release of ACTH induced by cachectin suggests that other mechanisms may be involved in the release of ACTH induced by this peptide. Since the concentrations of cachectin required to stimulate pituitary hormone release are similar to those that are encountered in plasma during infection, it is likely that this direct pituitary action has pathophysiological significance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564680      PMCID: PMC286924          DOI: 10.1073/pnas.86.7.2418

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Radioimmunoassay of cyclic AMP and cyclic GMP.

Authors:  G Brooker; J F Harper; W L Terasaki; R D Moylan
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Corticotropin-releasing activity of monokines.

Authors:  B M Woloski; E M Smith; W J Meyer; G M Fuller; J E Blalock
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

3.  Involvement of arachidonic acid metabolites in the control of hypothalamic-pituitary function.

Authors:  S R Ojeda; J Capdevila; G Snyder; S M McCann; A Negro-Vilar; J R Falck
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1985

4.  Effects of corticotropin-releasing factor, neurohypophyseal peptides, and catecholamines on pituitary function.

Authors:  C Rivier; W Vale
Journal:  Fed Proc       Date:  1985-01

5.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.

Authors:  D Caput; B Beutler; K Hartog; R Thayer; S Brown-Shimer; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Tumor necrosis factor-induced activation of peritoneal macrophages is regulated by prostaglandin E2 and cAMP.

Authors:  V Lehmmann; B Benninghoff; W Dröge
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

7.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.

Authors:  B A Beutler; I W Milsark; A Cerami
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

8.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Purification of rabbit tumor necrosis factor.

Authors:  S Abe; T Gatanaga; M Yamazaki; G Soma; D Mizuno
Journal:  FEBS Lett       Date:  1985-01-28       Impact factor: 4.124

View more
  10 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  The testicular effects of tumor necrosis factor.

Authors:  K Mealy; B Robinson; C F Millette; J Majzoub; D W Wilmore
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

Review 3.  Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain.

Authors:  P H Black
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

4.  Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells.

Authors:  A T Reder
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

5.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Authors:  S H Murch; V A Lamkin; M O Savage; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

6.  Tumor necrosis factor-alpha activates the human prolactin gene promoter via nuclear factor-kappaB signaling.

Authors:  Sönke Friedrichsen; Claire V Harper; Sabrina Semprini; Michael Wilding; Antony D Adamson; Dave G Spiller; Glyn Nelson; John J Mullins; Michael R H White; Julian R E Davis
Journal:  Endocrinology       Date:  2005-10-27       Impact factor: 4.736

7.  Estrogens modulate the inhibitory effect of tumor necrosis factor-alpha on anterior pituitary cell proliferation and prolactin release.

Authors:  S Theas; D Pisera; B Duvilanski; A De Laurentiis; M Pampillo; M Lasaga; A Seilicovich
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

8.  Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor.

Authors:  R Neta; R Perlstein; S N Vogel; G D Ledney; J Abrams
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

9.  Activation of the inflammatory transcription factor nuclear factor interleukin-6 during inflammatory and psychological stress in the brain.

Authors:  Franziska Fuchs; Jelena Damm; Rüdiger Gerstberger; Joachim Roth; Christoph Rummel
Journal:  J Neuroinflammation       Date:  2013-11-26       Impact factor: 8.322

10.  Age Dependent Hypothalamic and Pituitary Responses to Novel Environment Stress or Lipopolysaccharide in Rats.

Authors:  Sandy Koenig; Janne Bredehöft; Alexander Perniss; Franziska Fuchs; Joachim Roth; Christoph Rummel
Journal:  Front Behav Neurosci       Date:  2018-03-19       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.